Executive Editor

Elias Jabbour, MD

Executive Editor

Elias Jabbour, MD, is the D.B. Lane Cancer Research Fund Distinguished Professor in Leukemia Research, the Section Chief of Acute Lymphoblastic Leukemia, and Professor of Medicine in the Department of Leukemia, Division of Cancer Medicine, at MD Anderson Cancer Center in Houston.

Articles by Elias Jabbour, MD

Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse Live | May 23, 2024
The panel discussed ALL treatment, associated toxicities, and the possibility of a chemotherapy-free approach.
Listen Now
Elias Jabbour, MDPrint | May 22, 2024
In this executive editor's message, Elias Jabbour, MD, writes about redefining leukemias as curable or less curable.
Elias Jabbour, MDThe HemOnc Pulse Live | May 21, 2024
The panel mainly discussed frontline tyrosine kinase inhibitors for the treatment of chronic phase CML.
Elias Jabbour, MDChronic Lymphocytic Leukemia | March 29, 2024
Elias Jabbour, MD, discusses the latest news and novel therapies in CLL.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse: MRD | April 26, 2024
Elias Jabbour, MD, joined "The HemOnc Pulse" to discuss the function of MRD in treating ALL.
Elias Jabbour, MDPrint | January 4, 2024
The Blood Cancers Today Editorial Board offers their thoughts on the past year.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | October 19, 2023
Elias Jabbour, MD, discusses the most burning questions in acute lymphoblastic leukemia (ALL).
Elias Jabbour, MDAcute Lymphoblastic Leukemia | February 8, 2024
Dr. Jabbour presented data from the study at the Eleventh Annual Meeting of SOHO.
Elias Jabbour, MDAcute Lymphoblastic Leukemia | September 19, 2023
September is always an exciting time for SOHO members as the month brings the Annual Meeting in Houston, Texas. 
Sagar Lonial, MD, FACPViewpoints | February 8, 2024
The Blood Cancers Today Editorial Board reflects on the latest news in the field so far in 2023.
Leah SherwoodAcute Lymphoblastic Leukemia | February 8, 2024
Blood Cancers Today Associate Elias Jabbour, MD, gives an update from the 2023 EHA Congress.
Elias Jabbour, MDAcute Lymphoblastic Leukemia | June 12, 2023
We went from survival of 10% to 90% and from full-fledged chemotherapy and transplant to a chemotherapy-free regimen.
Elias Jabbour, MDViewpoints | January 4, 2023
As 2022 came to a close, the Blood Cancers Today Editorial Board shared their highlights from the year.
Chadi Nabhan, MD, MBA, FACPAcute Lymphoblastic Leukemia | February 1, 2023
Elias Jabbour, MD, chats with The HemOnc Pulse host Chadi Nabhan, MD, MBA, FACP, about ALL treatment advances at ASH 2022.